Baghdiguian S, Pichon J, Marvaldi J, Fantini J
INSERM unité 270, faculté de médecine nord, Marseille, France.
Bull Cancer. 1991;78(9):807-17.
Suramin is an anti-helminthic drug that has been shown to antagonize the effects of a variety of growth factors including EGF, PDGF and TGF beta. When added to the culture medium, suramin inhibited the proliferation of both human colonic adenocarcinoma cells HT29-D4 and rat glioma cells C6. Suramin also induced the differentiation of both cell lines: appearance of cellular extensions for C6 cells, enterocyte-like epithelial differentiation for HT29-D4-cells. In the latter case, suramin probably acts at the level of glucose metabolism, which is likely to be modulated by autocrine growth factors. The permanent secretion of such factors probably stimulates HT29-D4 proliferation and simultaneously inhibits their differentiation. It is hypothesized that interfering with this autocrine loop, suramin allows HT29-D4 cells to differentiate.
苏拉明是一种抗蠕虫药物,已被证明可拮抗多种生长因子的作用,包括表皮生长因子(EGF)、血小板衍生生长因子(PDGF)和转化生长因子β(TGFβ)。当添加到培养基中时,苏拉明抑制了人结肠腺癌细胞HT29-D4和大鼠胶质瘤细胞C6的增殖。苏拉明还诱导了这两种细胞系的分化:C6细胞出现细胞突起,HT29-D4细胞出现肠上皮样上皮分化。在后一种情况下,苏拉明可能作用于葡萄糖代谢水平,而葡萄糖代谢可能受自分泌生长因子的调节。这些因子的持续分泌可能刺激HT29-D4细胞增殖,同时抑制其分化。据推测,通过干扰这种自分泌循环,苏拉明使HT29-D4细胞得以分化。